首页> 外文OA文献 >Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536

【2h】

Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536

机译：Polo样激酶1（PLK1）作为慢性骨髓白血病的新药靶标：用PLK1抑制剂BI 2536覆盖伊替尼电阻

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
K. V. Gleixner; V. Ferenc; B. Peter; A. Gruze; R. A. Meyer; E. Hadzijusufovic; S. Cerny-Reiterer; M. Mayerhofer; W. F. Pickl; C. Sillaber; P. Valent;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. [J] . Gleixner KV, Ferenc V, Peter Cancer research: The official organ of the American Association for Cancer Research, Inc . 2010,第4期

机译：Polo样激酶1（Plk1）作为慢性粒细胞白血病的新型药物靶标：用Plk1抑制剂BI 2536取代了伊马替尼耐药性。
2. Preliminary Safety, Pharmacokinetics (PK) and Pharmacodynamic (PD) Analysis of the Polo-like Kinase-1 (PLK1) Inhibitor PCM-075, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (D) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) [J] . Zeidan Amer M., Schiller Gary J., Spira Alexander I., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：Polo样激酶-1（PLK1）抑制剂PCM-075的初步安全性，药代动力学（PK）和药物动力学（PD）分析与复发或难治性的患者中的低剂量糖苷（LDAC）或Degitabine（D）组合（R / R）急性髓性白血病（AML）
3. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells [J] . Biochemical and Biophysical Research Communications . 2020,第4期

机译：靶向对急性髓性白血病细胞中的双溴4（BRD4）和Polo样激酶1（PLK1）蛋白的嵌合分子靶向嵌合分子
4. Combination effects of repetitive pulsed magnetic stimulation and tyrosine kinase inhibitor imatinib for chronic myeloid leukemia cell line TCC-S [C] . S. Yamaguchi, M. Sekino, Y. Sato, Intermag Conference . 2006

机译：重复脉冲磁刺激和酪氨酸激酶抑制剂慢性髓性白血病细胞系TCC-S的组合效应
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. Structure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1) a Potential Drug Target in Schistosoma mansoni [O] . Thavy Long, R. Jeffrey Neitz, Rachel Beasley, 2016

机译：曼氏血吸虫潜在药物靶标的Polo样激酶1（PLK1）的苯并咪唑噻吩抑制剂的结构生物活性关系。
7. Structure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoni. [O] . Thavy Long, R Jeffrey Neitz, Rachel Beasley, 2016

机译：马来西亚血吸虫1（pLK1）的苯并咪唑噻吩抑制剂的结构 - 生物活性关系，pLK1是曼氏血吸虫的潜在药物靶标。

Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536

著录项

引文网络

相似文献

相关主题

期刊订阅